Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to …
MarketWatch (press release)
Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA …
Market Report — In Play (GSK)
MSN Money
GlaxoSmithKline and Regulus Therapeutics establish new collaboration to develop and commercialize microRNA Therapeutics Targeting miR-122 Co and Regulus …
Regulus, the MicroRNA Child of Isis and Alnylam, Strikes Potential $150M Deal …
Xconomy
Two years have passed since GlaxoSmithKline anointed a startup called Regulus Therapeutics as a leader in the bleeding-edge world of microRNA drugs, …
Related Posts
Regulus Provides Update on ‘Road to the Clinic’ Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
Silence Therapeutics Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics
Recent microRNA Press
Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21
Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
No related posts.
Loading ...
